Fibromyalgia Treatment: What the Evidence Shows

A 2013 Finding That Changed Everything

For decades, fibromyalgia was dismissed as a psychosomatic condition — pain without pathology. Then in 2013, a study published in Pain by Oaklander et al. reported that 41% of fibromyalgia patients had reduced intraepidermal nerve fiber density on skin punch biopsy, compared to 3% of controls. This finding of small fiber neuropathy (SFN) — objectively measurable damage to the thinnest, most pain-sensitive nerve fibers in the skin — provided the first histological evidence of a biological substrate in a subset of fibromyalgia patients. It did not make fibromyalgia a neuropathy, but it permanently changed the conversation.

Who Gets Fibromyalgia

Fibromyalgia affects approximately 4 million US adults, about 2% of the population. Women are diagnosed at roughly 7 times the rate of men, though this disparity may partly reflect diagnostic bias. Average age at diagnosis is 30–50 years. Fibromyalgia frequently coexists with other central sensitization syndromes: irritable bowel syndrome (30–70% overlap), interstitial cystitis, temporomandibular disorders, and chronic fatigue syndrome.

The Pathophysiology: Central Sensitization

The leading mechanistic framework for fibromyalgia is central sensitization — a state of amplified neural signaling in the central nervous system. In people with fibromyalgia, functional neuroimaging studies consistently show heightened activity in pain-processing brain regions (anterior cingulate cortex, insula) in response to stimuli that would not activate these regions in healthy controls. Conditioned pain modulation (CPM), which measures the brain's ability to inhibit pain signals via descending pathways, is measurably impaired.

Substance P levels in the cerebrospinal fluid of fibromyalgia patients are elevated 3-fold compared to controls. Glutamate concentrations in the insula are also elevated, tracked by proton magnetic resonance spectroscopy. These biochemical findings confirm that fibromyalgia is not imagined — it is a disorder of pain regulation.

Revised Diagnostic Criteria

The 2010 ACR criteria (updated 2016) replaced the outdated tender point examination with two validated scales: the Widespread Pain Index (WPI, 0–19 points) and the Symptom Severity Scale (SS, 0–12 points). A diagnosis requires WPI ≥7 and SS ≥5, or WPI 4–6 and SS ≥9, present for at least 3 months. This shift recognized that fibromyalgia is a whole-body syndrome, not simply a musculoskeletal condition.

FDA-Approved Pharmacological Treatments

Three drugs carry FDA approval specifically for fibromyalgia. Each addresses a different neurochemical pathway.

The number needed to treat (NNT) values of 7–12 reflect meaningful but modest efficacy. No single drug eliminates fibromyalgia pain. Combination strategies are common in clinical practice, though evidence for specific combinations is limited.

Drugs That Do Not Work

Opioids are not recommended for fibromyalgia. Multiple studies show no long-term benefit, and opioid-induced hyperalgesia can worsen central sensitization. NSAIDs have no proven efficacy for fibromyalgia pain specifically, though they may help comorbid musculoskeletal conditions. Tramadol has weak supporting data but carries significant dependence risk.

• Opioids: 2016 Cochrane review found no quality evidence supporting long-term opioid use in fibromyalgia; they are explicitly contraindicated in EULAR guidelines
• NSAIDs: no significant reduction in core fibromyalgia pain in controlled trials; useful only for comorbid inflammatory conditions
• Tramadol: some short-term evidence, but serotonergic effects and dependence risk limit use; combination with SNRIs risks serotonin syndrome
• Benzodiazepines: worsen restorative sleep architecture despite reducing anxiety; associated with cognitive impairment in fibromyalgia populations

Non-Pharmacological Treatments: The Stronger Evidence

Counterintuitively, non-pharmacological treatments show stronger and more durable effect sizes than medications for fibromyalgia.

• Aerobic exercise: the single most evidence-supported intervention; a 2017 Cochrane review found moderate-quality evidence for improvement in pain, physical function, and well-being
• Cognitive behavioral therapy (CBT): targets catastrophizing, which is a strong predictor of fibromyalgia severity; a 2010 meta-analysis found effect sizes of 0.37 for pain and 0.57 for functioning
• Mindfulness-based stress reduction (MBSR): 8-week programs show significant reductions in symptom severity scores; effect sizes are modest but sustained at 6-month follow-up
• Hydrotherapy/aquatic exercise: warm water reduces musculoskeletal load; particularly beneficial for those who cannot tolerate land-based exercise initially
• Sleep improvement: non-restorative sleep both results from and perpetuates fibromyalgia; treating comorbid sleep disorders (often with CBT-I or low-dose tricyclics) can reduce pain intensity

Multimodal Programs

Interdisciplinary programs combining pharmacological management, supervised exercise, and psychological therapy consistently outperform single-modality approaches. A 2009 meta-analysis by Häuser et al. in the Annals of Internal Medicine found that multimodal therapy produced significantly better outcomes than any unimodal treatment, with benefits maintained at 6–12 months.

This article is for informational purposes only. Consult a qualified healthcare professional.